<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01788150</url>
  </required_header>
  <id_info>
    <org_study_id>IP-12-002</org_study_id>
    <nct_id>NCT01788150</nct_id>
  </id_info>
  <brief_title>Safety and Efficacy Study of the Svelte Drug-Eluting Coronary Stent Delivery System</brief_title>
  <acronym>DIRECT II</acronym>
  <official_title>Direct Implantation of Rapamycin-Eluting Stents With Bio-Erodible Drug Carrier Technology Utilizing the Second Generation Svelte Drug-Eluting Coronary Stent Integrated Delivery System (IDS)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Svelte Medical Systems, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Svelte Medical Systems, Inc.</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      A prospective, randomized, active-control, multi-center clinical trial comparing the safety&#xD;
      and efficacy of the Svelte Drug-Eluting Coronary Stent Integrated Delivery System (IDS) to&#xD;
      that of the commercially available Resolute IntegrityTM Drug-Eluting Stent.&#xD;
&#xD;
      The study objective is to assess the safety and efficacy of the Svelte Drug-Eluting Coronary&#xD;
      Stent Integrated Delivery System (IDS) compared to the Resolute IntegrityTM Drug-Eluting&#xD;
      Stent in patients with single, never previously treated coronary artery lesions&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">January 2013</start_date>
  <completion_date type="Actual">May 31, 2019</completion_date>
  <primary_completion_date type="Actual">May 2014</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Angiographic In-Stent Late Lumen Loss (LL)</measure>
    <time_frame>6-months post-procedure</time_frame>
    <description>Defined as the measurements either within the stented segment or within 5 mm proximal and distal to the stent edges.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Number of Participants Clinically-driven Target Lesion Revascularization (TLR)</measure>
    <time_frame>1 year post-procedure</time_frame>
    <description>Clinically driven TLR is defined as revascularization performed on a patient who returns with clinical symptoms such as unstable angina, that is, chest pain that increases in frequency, intensity or duration.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants Composite of Cardiac Death, MI Attributed to the Target Vessel and Clinically Driven Target Lesion Revascularization</measure>
    <time_frame>1 year post-procedure</time_frame>
    <description>Composite of cardiac death, MI attributed to the target vessel and clinically driven target lesion revascularization</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants Composite of All-cause Mortality, Any MI and Any Revascularization, Target Vessel Revascularization or Revascularization of Non Target Vessels</measure>
    <time_frame>1 year post-procedure</time_frame>
    <description>Composite of all-cause mortality, any MI and any revascularization, target vessel revascularization or revascularization of non target vessels</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants Stent Thrombosis</measure>
    <time_frame>1 year post-procedure</time_frame>
    <description>The sudden occlusion of a stented coronary artery due to thrombus formation.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants Acute Success Rates</measure>
    <time_frame>From index procedure to hospital discharge, an average of 24 hours</time_frame>
    <description>Direct Stenting Success, Lesion Success, Procedure Success and Device Failure</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants In-stent and In-segment Angiographic Binary Restenosis Rate</measure>
    <time_frame>6-months post-procedure</time_frame>
    <description>The rate which restenosis occurs</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>In-stent and In-segment Minimum Lumen Diameter</measure>
    <time_frame>6-months post-procedure</time_frame>
    <description>Smallest diameter in the stent or segment area</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>In-segment Late Lumen Loss</measure>
    <time_frame>6-months post-procedure</time_frame>
    <description>Late lumen loss is the difference in millimeters between the diameter of a stented segment post-procedure compared with the follow-up angiogram</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Neointimal Hyperplasia as Measured by OCT</measure>
    <time_frame>6-months post procedures</time_frame>
    <description>(% lumen volume)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Strut Coverage</measure>
    <time_frame>6-months post procedure</time_frame>
    <description>(% of struts malapposed, protruding non-covered, protruding covered, non-protruding covered)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants Target Vessel Failure</measure>
    <time_frame>1 year post procedure</time_frame>
    <description>Composite endpoint of cardiac death, target vessel MI (Q or Non-Q wave), or clinically- driven target vessel revascularization (TVR) by percutaneous or surgical methods.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">159</enrollment>
  <condition>Coronary Artery Disease</condition>
  <arm_group>
    <arm_group_label>Svelte Drug-Eluting Coronary Stent</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Coronary Stenting</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Medtronic Resolute Integrity Drug-Eluting Stent</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Coronary Stenting</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Coronary Stenting</intervention_name>
    <arm_group_label>Medtronic Resolute Integrity Drug-Eluting Stent</arm_group_label>
    <arm_group_label>Svelte Drug-Eluting Coronary Stent</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
        General Inclusion Criteria&#xD;
&#xD;
          1. Patient is ≥18 years old;&#xD;
&#xD;
          2. Patient is eligible for percutaneous coronary intervention (PCI);&#xD;
&#xD;
          3. Patient is an acceptable candidate for emergent coronary artery bypass graft (CABG)&#xD;
             surgery;&#xD;
&#xD;
          4. Patient has clinical evidence of ischemic heart disease, stable or unstable angina,&#xD;
             silent ischemia, or a positive functional study;&#xD;
&#xD;
          5. Female subjects of childbearing potential must have a negative pregnancy test within&#xD;
             7-days before the trial procedure;&#xD;
&#xD;
          6. Patient or subject's legal representative has been informed of the nature of the trial&#xD;
             and agrees to its provisions and has provided written informed consent as approved by&#xD;
             the Hospital Research Ethics Committee (HREC) of the respective investigational site;&#xD;
             and&#xD;
&#xD;
          7. Patient agrees to comply with specified follow-up evaluations and to return to the&#xD;
             same investigational site where the procedure was performed.&#xD;
&#xD;
        Angiographic Inclusion Criteria&#xD;
&#xD;
          1. Patient has either a single target lesion, or two lesions (target and non-target)&#xD;
             located in separate coronary arteries;&#xD;
&#xD;
          2. If a non-target lesion is treated, it must be treated first and only with commercially&#xD;
             available PTCA balloons and/or stents. Post PCI of the non-target vessel, all of the&#xD;
             following conditions must be met:&#xD;
&#xD;
               1. Residual diameter stenosis &lt; 30%;&#xD;
&#xD;
               2. Absence of any angiographic complications;&#xD;
&#xD;
               3. Absence of ischemic symptoms; and&#xD;
&#xD;
               4. Absence of significant new arrhythmia or ECG monitoring changes suggestive of&#xD;
                  ischemia.&#xD;
&#xD;
          3. Reference vessel ≥ 2.5 mm and ≤ 3.5 mm in diameter by visual estimate;&#xD;
&#xD;
          4. Target lesion &lt; 20 mm in length by visual estimate (the intention is to cover the&#xD;
             entire lesion with one stent of adequate length); and&#xD;
&#xD;
          5. Target lesion stenosis ≥ 50% and &lt; 100% by visual estimate.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
        General Exclusion Criteria&#xD;
&#xD;
          1. Patient is currently enrolled in another investigational device or drug trial that has&#xD;
             not completed the primary endpoint or that clinically interferes with the current&#xD;
             study endpoints Note: Trials requiring extended follow-up for products that were&#xD;
             investigational, but have since become commercially available, are not considered&#xD;
             investigational trials;&#xD;
&#xD;
          2. The patient requires a staged procedure of the target vessel within 6-months or a&#xD;
             staged procedure of a non-target vessel within 30-days post-procedure;&#xD;
&#xD;
          3. The target lesion requires treatment with a device other than PTCA prior to stent&#xD;
             placement (such as, but not limited to, directional coronary atherectomy, excimer&#xD;
             laser, rotational atherectomy, etc.);&#xD;
&#xD;
          4. Any DES deployment anywhere in the target vessel within the past 9-months;&#xD;
&#xD;
          5. Any BMS deployment anywhere in the target vessel within the past 6-months;&#xD;
&#xD;
          6. Any previous stent placement within 10 mm (proximal or distal) of the target lesion;&#xD;
&#xD;
          7. Myocardial infarction within 72-hours of the index procedure, with the exception of:&#xD;
&#xD;
               1. Patients who have had a STEMI and PCI to the culprit lesion may be included if&#xD;
                  they have a suitable lesion in another vessel, and have been clinically and&#xD;
                  hemodynamically stable for 72-hours;&#xD;
&#xD;
               2. Patients who have had a non-STEMI may be included if their troponin levels are&#xD;
                  within the laboratory normal range within 24-hours pre-procedure.&#xD;
&#xD;
          8. Co-morbid condition(s) that could limit the patient's ability to participate in the&#xD;
             trial or to comply with follow-up requirements, or impact the scientific integrity of&#xD;
             the trial;&#xD;
&#xD;
          9. Concurrent medical condition with a life expectancy of less than 12-months;&#xD;
&#xD;
         10. Documented left ventricular ejection fraction (LVEF) ≤ 30%;&#xD;
&#xD;
         11. Unstable angina pectoris from an extra-cardiac cause (Braunwald Class A I-III);&#xD;
&#xD;
         12. Known allergies to the following: Acetylsalicylic acid (ASA), Clopidogrel bisulfate,&#xD;
             Ticlopidine, Prasugrel, Rapamycin, Zotarolimus, PEAIII AcBz, Heparin/ Bivalirudin, or&#xD;
             contrast agent (that cannot be adequately premedicated);&#xD;
&#xD;
         13. Platelet count &lt; 100,000 cells/mm3 or &gt; 700,000 cells/mm3 or a WBC &lt; 3.000 cells/mm3&#xD;
             or hemoglobin &lt; 100g/l;&#xD;
&#xD;
         14. Acute or chronic renal dysfunction (serum creatinine &gt; 170μmol/L);&#xD;
&#xD;
         15. History of a stroke or transient ischemic attack (TIA) within the prior 6-months;&#xD;
&#xD;
         16. Active peptic ulcer or upper gastrointestinal (GI) bleeding within the prior 6-months;&#xD;
&#xD;
         17. History of bleeding diathesis or coagulopathy or will refuse blood transfusions; and&#xD;
&#xD;
         18. Patients requiring ongoing anticoagulation with warfarin or dabigatran.&#xD;
&#xD;
        Angiographic Exclusion Criteria&#xD;
&#xD;
          1. Total occlusion (TIMI 0 or 1);&#xD;
&#xD;
          2. Target vessel has angiographic evidence of thrombus&#xD;
&#xD;
          3. Target vessel is excessively tortuous or has heavy calcification;&#xD;
&#xD;
          4. Significant (&gt; 50%) stenosis proximal or distal to the target lesion that might&#xD;
             require revascularization or impede run off;&#xD;
&#xD;
          5. Target lesion is located in or supplied by an arterial or venous bypass graft;&#xD;
&#xD;
          6. Ostial target lesion (within 5.0 mm of vessel origin) or any location within the left&#xD;
             main coronary artery;&#xD;
&#xD;
          7. Target lesion involves a side branch &gt; 2.0 mm in diameter; and&#xD;
&#xD;
          8. Unprotected Left Main coronary disease (stenosis &gt; 50%).&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Stefan Verheye, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Antwerp Cardiovascular Institute</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Alexandre Abizaid, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Instituto Dante Pazzanese de Cardiologia</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>OLV Ziekenhuis Aalst</name>
      <address>
        <city>Aalst</city>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Middelheim Ziekenhuis</name>
      <address>
        <city>Antwerpen</city>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>ZOL Genk</name>
      <address>
        <city>Genk</city>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CHU Liège</name>
      <address>
        <city>Liege</city>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Všeobecná fakultní nemocnice Praha</name>
      <address>
        <city>Prague</city>
        <country>Czechia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clinique Saint-Hilaire</name>
      <address>
        <city>Rouen</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CHU de Toulouse</name>
      <address>
        <city>Toulouse</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clinique Pasteur</name>
      <address>
        <city>Toulouse</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Medizinisches Verzorgungszentrum Prof. Mathey, Prof. Schofer</name>
      <address>
        <city>Hamburg</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University Medical Center Hamburg-Eppendorf</name>
      <address>
        <city>Hamburg</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>OLVG Amsterdam</name>
      <address>
        <city>Amsterdam</city>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Catharina Hospital Eindhoven</name>
      <address>
        <city>Eindhoven</city>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Erasmus MC</name>
      <address>
        <city>Rotterdam</city>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Maasstad Ziekenhuis</name>
      <address>
        <city>Rotterdam</city>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University Medical Center Utrecht, Department of Cardiology</name>
      <address>
        <city>Utrecht</city>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Skane University Hospital</name>
      <address>
        <city>Malmo</city>
        <country>Sweden</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Södersjukhuset</name>
      <address>
        <city>Stockholm</city>
        <country>Sweden</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Inselspital</name>
      <address>
        <city>Bern</city>
        <country>Switzerland</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Belgium</country>
    <country>Czechia</country>
    <country>France</country>
    <country>Germany</country>
    <country>Netherlands</country>
    <country>Sweden</country>
    <country>Switzerland</country>
  </location_countries>
  <removed_countries>
    <country>Brazil</country>
    <country>Czech Republic</country>
  </removed_countries>
  <link>
    <url>http://www.sveltemedical.com</url>
    <description>Related Info</description>
  </link>
  <verification_date>April 2021</verification_date>
  <study_first_submitted>February 5, 2013</study_first_submitted>
  <study_first_submitted_qc>February 7, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 11, 2013</study_first_posted>
  <results_first_submitted>March 16, 2021</results_first_submitted>
  <results_first_submitted_qc>April 9, 2021</results_first_submitted_qc>
  <results_first_posted type="Actual">May 4, 2021</results_first_posted>
  <last_update_submitted>April 9, 2021</last_update_submitted>
  <last_update_submitted_qc>April 9, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">May 4, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Coronary Artery Disease</mesh_term>
  </condition_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Svelte Drug-Eluting Coronary Stent</title>
          <description>Coronary Stenting&#xD;
Coronary Stenting</description>
        </group>
        <group group_id="P2">
          <title>Medtronic Resolute Integrity Drug-Eluting Stent</title>
          <description>Coronary Stenting&#xD;
Coronary Stenting</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="108"/>
                <participants group_id="P2" count="51"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="95"/>
                <participants group_id="P2" count="48"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="13"/>
                <participants group_id="P2" count="3"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Svelte Drug-Eluting Coronary Stent</title>
          <description>Coronary Stenting&#xD;
Coronary Stenting</description>
        </group>
        <group group_id="B2">
          <title>Medtronic Resolute Integrity Drug-Eluting Stent</title>
          <description>Coronary Stenting&#xD;
Coronary Stenting</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="108"/>
            <count group_id="B2" value="51"/>
            <count group_id="B3" value="159"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="62.7" spread="9.9"/>
                    <measurement group_id="B2" value="64.2" spread="12.4"/>
                    <measurement group_id="B3" value="63.2" spread="10.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="26"/>
                    <measurement group_id="B2" value="17"/>
                    <measurement group_id="B3" value="43"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="82"/>
                    <measurement group_id="B2" value="34"/>
                    <measurement group_id="B3" value="116"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Netherlands</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="33"/>
                    <measurement group_id="B2" value="20"/>
                    <measurement group_id="B3" value="53"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Sweden</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Belgium</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="24"/>
                    <measurement group_id="B2" value="16"/>
                    <measurement group_id="B3" value="40"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Czechia</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                    <measurement group_id="B2" value="5"/>
                    <measurement group_id="B3" value="8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>France</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="26"/>
                    <measurement group_id="B2" value="6"/>
                    <measurement group_id="B3" value="32"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Switzerland</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="14"/>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="16"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Germany</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="7"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Angiographic In-Stent Late Lumen Loss (LL)</title>
        <description>Defined as the measurements either within the stented segment or within 5 mm proximal and distal to the stent edges.</description>
        <time_frame>6-months post-procedure</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Svelte Drug-Eluting Coronary Stent</title>
            <description>Coronary Stenting&#xD;
Coronary Stenting</description>
          </group>
          <group group_id="O2">
            <title>Medtronic Resolute Integrity Drug-Eluting Stent</title>
            <description>Coronary Stenting&#xD;
Coronary Stenting</description>
          </group>
        </group_list>
        <measure>
          <title>Angiographic In-Stent Late Lumen Loss (LL)</title>
          <description>Defined as the measurements either within the stented segment or within 5 mm proximal and distal to the stent edges.</description>
          <units>mm</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="89"/>
                <count group_id="O2" value="40"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.09" spread="0.31"/>
                    <measurement group_id="O2" value="0.13" spread="0.27"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants Clinically-driven Target Lesion Revascularization (TLR)</title>
        <description>Clinically driven TLR is defined as revascularization performed on a patient who returns with clinical symptoms such as unstable angina, that is, chest pain that increases in frequency, intensity or duration.</description>
        <time_frame>1 year post-procedure</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Svelte Drug-Eluting Coronary Stent</title>
            <description>Coronary Stenting&#xD;
Coronary Stenting</description>
          </group>
          <group group_id="O2">
            <title>Medtronic Resolute Integrity Drug-Eluting Stent</title>
            <description>Coronary Stenting&#xD;
Coronary Stenting</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants Clinically-driven Target Lesion Revascularization (TLR)</title>
          <description>Clinically driven TLR is defined as revascularization performed on a patient who returns with clinical symptoms such as unstable angina, that is, chest pain that increases in frequency, intensity or duration.</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="108"/>
                <count group_id="O2" value="51"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                    <measurement group_id="O2" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants Composite of Cardiac Death, MI Attributed to the Target Vessel and Clinically Driven Target Lesion Revascularization</title>
        <description>Composite of cardiac death, MI attributed to the target vessel and clinically driven target lesion revascularization</description>
        <time_frame>1 year post-procedure</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Svelte Drug-Eluting Coronary Stent</title>
            <description>Coronary Stenting&#xD;
Coronary Stenting</description>
          </group>
          <group group_id="O2">
            <title>Medtronic Resolute Integrity Drug-Eluting Stent</title>
            <description>Coronary Stenting&#xD;
Coronary Stenting</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants Composite of Cardiac Death, MI Attributed to the Target Vessel and Clinically Driven Target Lesion Revascularization</title>
          <description>Composite of cardiac death, MI attributed to the target vessel and clinically driven target lesion revascularization</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="108"/>
                <count group_id="O2" value="51"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4"/>
                    <measurement group_id="O2" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants Composite of All-cause Mortality, Any MI and Any Revascularization, Target Vessel Revascularization or Revascularization of Non Target Vessels</title>
        <description>Composite of all-cause mortality, any MI and any revascularization, target vessel revascularization or revascularization of non target vessels</description>
        <time_frame>1 year post-procedure</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Svelte Drug-Eluting Coronary Stent</title>
            <description>Coronary Stenting&#xD;
Coronary Stenting</description>
          </group>
          <group group_id="O2">
            <title>Medtronic Resolute Integrity Drug-Eluting Stent</title>
            <description>Coronary Stenting&#xD;
Coronary Stenting</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants Composite of All-cause Mortality, Any MI and Any Revascularization, Target Vessel Revascularization or Revascularization of Non Target Vessels</title>
          <description>Composite of all-cause mortality, any MI and any revascularization, target vessel revascularization or revascularization of non target vessels</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="108"/>
                <count group_id="O2" value="51"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="18"/>
                    <measurement group_id="O2" value="9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants Stent Thrombosis</title>
        <description>The sudden occlusion of a stented coronary artery due to thrombus formation.</description>
        <time_frame>1 year post-procedure</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Svelte Drug-Eluting Coronary Stent</title>
            <description>Coronary Stenting&#xD;
Coronary Stenting</description>
          </group>
          <group group_id="O2">
            <title>Medtronic Resolute Integrity Drug-Eluting Stent</title>
            <description>Coronary Stenting&#xD;
Coronary Stenting</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants Stent Thrombosis</title>
          <description>The sudden occlusion of a stented coronary artery due to thrombus formation.</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="108"/>
                <count group_id="O2" value="51"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants Acute Success Rates</title>
        <description>Direct Stenting Success, Lesion Success, Procedure Success and Device Failure</description>
        <time_frame>From index procedure to hospital discharge, an average of 24 hours</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Svelte Drug-Eluting Coronary Stent</title>
            <description>Coronary Stenting&#xD;
Coronary Stenting</description>
          </group>
          <group group_id="O2">
            <title>Medtronic Resolute Integrity Drug-Eluting Stent</title>
            <description>Coronary Stenting&#xD;
Coronary Stenting</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants Acute Success Rates</title>
          <description>Direct Stenting Success, Lesion Success, Procedure Success and Device Failure</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="108"/>
                <count group_id="O2" value="51"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Device Failure</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Direct Stenting Success</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="96"/>
                    <measurement group_id="O2" value="45"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Lesion Success</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="104"/>
                    <measurement group_id="O2" value="51"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Procedure Success</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="103"/>
                    <measurement group_id="O2" value="48"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants In-stent and In-segment Angiographic Binary Restenosis Rate</title>
        <description>The rate which restenosis occurs</description>
        <time_frame>6-months post-procedure</time_frame>
        <population>19 Subjects in the Svelte Arm and 11 subjects in the Medtronic Arm did not return for their 6 month follow-up or refused to have the invasive follow-up</population>
        <group_list>
          <group group_id="O1">
            <title>Svelte Drug-Eluting Coronary Stent</title>
            <description>Coronary Stenting&#xD;
Coronary Stenting</description>
          </group>
          <group group_id="O2">
            <title>Medtronic Resolute Integrity Drug-Eluting Stent</title>
            <description>Coronary Stenting&#xD;
Coronary Stenting</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants In-stent and In-segment Angiographic Binary Restenosis Rate</title>
          <description>The rate which restenosis occurs</description>
          <population>19 Subjects in the Svelte Arm and 11 subjects in the Medtronic Arm did not return for their 6 month follow-up or refused to have the invasive follow-up</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="89"/>
                <count group_id="O2" value="40"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>In-stent angiographic binary restenosis rate</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>In-segment angiographic binary restenosis rate</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>In-stent and In-segment Minimum Lumen Diameter</title>
        <description>Smallest diameter in the stent or segment area</description>
        <time_frame>6-months post-procedure</time_frame>
        <population>19 Subjects in the Svelte Arm and 11 subjects in the Medtronic Arm did not return for their 6 month follow-up or refused to have the invasive follow-up</population>
        <group_list>
          <group group_id="O1">
            <title>Svelte Drug-Eluting Coronary Stent</title>
            <description>Coronary Stenting&#xD;
Coronary Stenting</description>
          </group>
          <group group_id="O2">
            <title>Medtronic Resolute Integrity Drug-Eluting Stent</title>
            <description>Coronary Stenting&#xD;
Coronary Stenting</description>
          </group>
        </group_list>
        <measure>
          <title>In-stent and In-segment Minimum Lumen Diameter</title>
          <description>Smallest diameter in the stent or segment area</description>
          <population>19 Subjects in the Svelte Arm and 11 subjects in the Medtronic Arm did not return for their 6 month follow-up or refused to have the invasive follow-up</population>
          <units>mm</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="89"/>
                <count group_id="O2" value="40"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>In-stent minimum lumen diameter</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.28" spread="0.46"/>
                    <measurement group_id="O2" value="2.52" spread="0.45"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>In-segment minimum lumen diameter</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.07" spread="0.48"/>
                    <measurement group_id="O2" value="2.26" spread="0.48"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>In-segment Late Lumen Loss</title>
        <description>Late lumen loss is the difference in millimeters between the diameter of a stented segment post-procedure compared with the follow-up angiogram</description>
        <time_frame>6-months post-procedure</time_frame>
        <population>19 Subjects in the Svelte Arm and 11 subjects in the Medtronic Arm did not return for their 6 month follow-up or refused to have the invasive follow-up</population>
        <group_list>
          <group group_id="O1">
            <title>Svelte Drug-Eluting Coronary Stent</title>
            <description>Coronary Stenting&#xD;
Coronary Stenting</description>
          </group>
          <group group_id="O2">
            <title>Medtronic Resolute Integrity Drug-Eluting Stent</title>
            <description>Coronary Stenting&#xD;
Coronary Stenting</description>
          </group>
        </group_list>
        <measure>
          <title>In-segment Late Lumen Loss</title>
          <description>Late lumen loss is the difference in millimeters between the diameter of a stented segment post-procedure compared with the follow-up angiogram</description>
          <population>19 Subjects in the Svelte Arm and 11 subjects in the Medtronic Arm did not return for their 6 month follow-up or refused to have the invasive follow-up</population>
          <units>mm</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="89"/>
                <count group_id="O2" value="40"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.04" spread="0.33"/>
                    <measurement group_id="O2" value="-0.02" spread="0.30"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Neointimal Hyperplasia as Measured by OCT</title>
        <description>(% lumen volume)</description>
        <time_frame>6-months post procedures</time_frame>
        <population>8 Subjects in the Svelte Arm refused to have the follow-up OCT at 6 months. This was only measureed in the Svelte arm.</population>
        <group_list>
          <group group_id="O1">
            <title>Svelte Drug-Eluting Coronary Stent</title>
            <description>Coronary Stenting&#xD;
Coronary Stenting</description>
          </group>
        </group_list>
        <measure>
          <title>Neointimal Hyperplasia as Measured by OCT</title>
          <description>(% lumen volume)</description>
          <population>8 Subjects in the Svelte Arm refused to have the follow-up OCT at 6 months. This was only measureed in the Svelte arm.</population>
          <units>percentage of lumen volume</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="22"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="11.3" spread="4.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Strut Coverage</title>
        <description>(% of struts malapposed, protruding non-covered, protruding covered, non-protruding covered)</description>
        <time_frame>6-months post procedure</time_frame>
        <population>8 Subjects in the Svelte Arm refused to have the follow-up OCT at 6 months. This was only measured int he Svelte arm</population>
        <group_list>
          <group group_id="O1">
            <title>Svelte Drug-Eluting Coronary Stent</title>
            <description>Coronary Stenting&#xD;
Coronary Stenting</description>
          </group>
        </group_list>
        <measure>
          <title>Strut Coverage</title>
          <description>(% of struts malapposed, protruding non-covered, protruding covered, non-protruding covered)</description>
          <population>8 Subjects in the Svelte Arm refused to have the follow-up OCT at 6 months. This was only measured int he Svelte arm</population>
          <units>% strut coverage</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="22"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="94.2" spread="9.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants Target Vessel Failure</title>
        <description>Composite endpoint of cardiac death, target vessel MI (Q or Non-Q wave), or clinically- driven target vessel revascularization (TVR) by percutaneous or surgical methods.</description>
        <time_frame>1 year post procedure</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Svelte Drug-Eluting Coronary Stent</title>
            <description>Coronary Stenting&#xD;
Coronary Stenting</description>
          </group>
          <group group_id="O2">
            <title>Medtronic Resolute Integrity Drug-Eluting Stent</title>
            <description>Coronary Stenting&#xD;
Coronary Stenting</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants Target Vessel Failure</title>
          <description>Composite endpoint of cardiac death, target vessel MI (Q or Non-Q wave), or clinically- driven target vessel revascularization (TVR) by percutaneous or surgical methods.</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="108"/>
                <count group_id="O2" value="51"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7"/>
                    <measurement group_id="O2" value="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>Svelte Drug-Eluting Coronary Stent</title>
          <description>Coronary Stenting&#xD;
Coronary Stenting</description>
        </group>
        <group group_id="E2">
          <title>Medtronic Resolute Integrity Drug-Eluting Stent</title>
          <description>Coronary Stenting&#xD;
Coronary Stenting</description>
        </group>
      </group_list>
      <serious_events>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="108"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="51"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="21" subjects_at_risk="108"/>
                <counts group_id="E2" subjects_affected="8" subjects_at_risk="51"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Angina</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="108"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="51"/>
              </event>
              <event>
                <sub_title>Arrhythmia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="108"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="51"/>
              </event>
              <event>
                <sub_title>Cardiac decompensation</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="108"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="51"/>
              </event>
              <event>
                <sub_title>Silent Ischemia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="108"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="51"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Endocrine disorders</title>
            <event_list>
              <event>
                <sub_title>HYperthyroidism</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="108"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="51"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>GI Bleed</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="108"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="51"/>
              </event>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="108"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="51"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Atypical Chest Pain</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="108"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="51"/>
              </event>
              <event>
                <sub_title>Chest pain wihtout cardiac enzyme elevation</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="108"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="51"/>
              </event>
              <event>
                <sub_title>Black-out after drinking wine</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="108"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="51"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Immune system disorders</title>
            <event_list>
              <event>
                <sub_title>Fever/Pyrexia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="108"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="51"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Local Infection</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="108"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="51"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Arthralgia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="108"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="51"/>
              </event>
              <event>
                <sub_title>Arthritis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="108"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="51"/>
              </event>
              <event>
                <sub_title>Back Pain</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="108"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="51"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Neoplasms benign, malignant and unspecified (incl cysts and polyps)</title>
            <event_list>
              <event>
                <sub_title>Endometrium Carcinoma</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="108"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="51"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Depression</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="108"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="51"/>
              </event>
              <event>
                <sub_title>Fainting/Syncope/Vasovagal Reaction</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="108"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="51"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Renal Failure/Insufficiency</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="108"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="51"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Bronchitis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="108"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="51"/>
              </event>
              <event>
                <sub_title>Other respiratory</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="108"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="51"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Carotid Stenosis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="108"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="51"/>
              </event>
              <event>
                <sub_title>Claudication</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="108"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="51"/>
              </event>
              <event>
                <sub_title>Restenosis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="108"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="51"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="36" subjects_at_risk="108"/>
                <counts group_id="E2" subjects_affected="14" subjects_at_risk="51"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>MI</sub_title>
                <counts group_id="E1" events="13" subjects_affected="13" subjects_at_risk="108"/>
                <counts group_id="E2" events="11" subjects_affected="11" subjects_at_risk="51"/>
              </event>
              <event>
                <sub_title>Elevated cardiac enzymes</sub_title>
                <counts group_id="E1" events="8" subjects_affected="8" subjects_at_risk="108"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="51"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Atypical Chest pain</sub_title>
                <counts group_id="E1" events="6" subjects_affected="6" subjects_at_risk="108"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="51"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Dissection</sub_title>
                <counts group_id="E1" events="9" subjects_affected="9" subjects_at_risk="108"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="51"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Betsy Lowry</name_or_title>
      <organization>Svelte Medical</organization>
      <phone>19082642181</phone>
      <email>blowry@sveltemedical.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

